Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Med J Aust. 2011 Apr 4;194(7):353-8. doi: 10.5694/j.1326-5377.2011.tb03006.x.
Clostridium difficile is the most common cause of health care-associated and antibiotic-associated diarrhoea. These guidelines are intended to provide advice to clinicians on the clinical assessment, diagnosis and management of C. difficile infection (CDI). Hypervirulent strains of C. difficile, including PCR ribotype 027 strains recently identified in Australia, have been associated elsewhere with epidemic spread and high rates of severe disease and death. Diagnostic tests include stool culture, polymerase chain reaction-based assays, cell-culture cytotoxicity assays and enzyme immunoassays detecting C. difficile glutamate dehydrogenase, and/or toxin A and/or B. To treat an initial episode and a first recurrence, metronidazole is the preferred antibiotic, with oral vancomycin reserved for severe disease and subsequent recurrences. Surgery should be considered for fulminant disease.
艰难梭菌是最常见的与医疗保健相关和与抗生素相关的腹泻的原因。本指南旨在为临床医生提供艰难梭菌感染(CDI)的临床评估、诊断和管理方面的建议。艰难梭菌的高毒力菌株,包括最近在澳大利亚发现的 PCR 核糖型 027 株,与其他地方的流行传播以及高严重疾病和死亡率有关。诊断测试包括粪便培养、聚合酶链反应检测、细胞培养细胞毒性检测和酶免疫分析检测艰难梭菌谷氨酸脱氢酶和/或毒素 A 和/或 B。治疗初始发作和首次复发时,甲硝唑是首选抗生素,口服万古霉素保留用于严重疾病和随后的复发。对于暴发性疾病,应考虑手术。